- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01136408
A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Aki-gun, Hiroshima, Japani
- 1160.49.024 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japani
- 1160.49.025 Boehringer Ingelheim Investigational Site
-
Fukuoka, Fukuoka, Japani
- 1160.49.026 Boehringer Ingelheim Investigational Site
-
Himeji, Hyogo, Japani
- 1160.49.021 Boehringer Ingelheim Investigational Site
-
Iizuka,Fukuoka, Japani
- 1160.49.027 Boehringer Ingelheim Investigational Site
-
Kyoto, Kyoto, Japani
- 1160.49.013 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japani
- 1160.49.011 Boehringer Ingelheim Investigational Site
-
Nagoya, Aichi, Japani
- 1160.49.012 Boehringer Ingelheim Investigational Site
-
Naka-gun, Ibaragi, Japani
- 1160.49.004 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japani
- 1160.49.022 Boehringer Ingelheim Investigational Site
-
Okayama, Okayama, Japani
- 1160.49.023 Boehringer Ingelheim Investigational Site
-
Oota, Tokyo, Japani
- 1160.49.006 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japani
- 1160.49.016 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japani
- 1160.49.017 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japani
- 1160.49.018 Boehringer Ingelheim Investigational Site
-
Osaka, Osaka, Japani
- 1160.49.019 Boehringer Ingelheim Investigational Site
-
Sakai, Osaka, Japani
- 1160.49.020 Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japani
- 1160.49.001 Boehringer Ingelheim Investigational Site
-
Sapporo, Hokkaido, Japani
- 1160.49.028 Boehringer Ingelheim Investigational Site
-
Sendai, Miyagi, Japani
- 1160.49.002 Boehringer Ingelheim Investigational Site
-
Shinjuku, Tokyo, Japani
- 1160.49.005 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japani
- 1160.49.014 Boehringer Ingelheim Investigational Site
-
Suita, Osaka, Japani
- 1160.49.015 Boehringer Ingelheim Investigational Site
-
Tokorozawa, Saitama, Japani
- 1160.49.007 Boehringer Ingelheim Investigational Site
-
Toyama, Toyama, Japani
- 1160.49.009 Boehringer Ingelheim Investigational Site
-
Tsuchiura, Ibaragi, Japani
- 1160.49.003 Boehringer Ingelheim Investigational Site
-
Ueda, Nagano, Japani
- 1160.49.029 Nagano National Hospital
-
Yokohama, Kanagawa, Japani
- 1160.49.008 Boehringer Ingelheim Investigational Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion criteria Inclusion criteria
- Patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
Patients who had additional risk factor for thromboembolism; one or more of the following conditions/events:
- Hypertension
- Diabetes mellitus
- Left-side heart failure
- A previous ischemic stroke or transient ischemic attack
- Age 75 years or older
- A history of coronary artery diseases
Exclusion criteria Exclusion criteria
- Patients diagnosed as having a valvular heart disease by echocardiography, or patients who had a history of prosthetic valve replacement or valve surgery
- Patients who were to receive electric defibrillation or pharmacological defibrillation during the study period
- Patients who developed stroke or transient ischemic attack within 30 days before the date of informed consent
- Patients who developed myocardial infarction or were admitted to hospital due to acute coronary syndrome or for percutaneous transluminal coronary angioplasty within 3 months before the date of informed consent or patients underwent coronary stenting within 6 months before the date of informed consent
- Patients with atrial myxoma or left ventricular thrombosis
- Patients with contraindication to anticoagulant therapies
- Patients scheduled for major surgery or invasive procedure
- Patients having major bleeding from non-gastrointestinal organs within 6 months before the date of informed consent
- Patients with uncontrolled hypertension
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Dabigatran etexilate 220 mg daily
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
|
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Kokeellinen: Dabigatran etexilate 300 mg daily
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Dabigatran etexilate 150 mg capsule, twice a day, oral administration
|
Active Comparator: Warfarin
Dose-adjusted warfarin based on target INR values
|
Varfariinin annossovitettu INR-tavoitearvojen perusteella
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Frequency (Occurrence Rates) of Major Bleeding Event
Aikaikkuna: upto 15 weeks
|
The percentage of patients with major bleeding event. Major bleeding was defined as any bleed fulfilling one of the following conditions:
|
upto 15 weeks
|
Frequency (Occurrence Rates) of Clinically Relevant Bleeding Event
Aikaikkuna: upto 15 weeks
|
The percentage of patients with clinically relevant bleeding event. Any bleed that did not qualify as a major bleed was defined as a minor bleed; minor bleed which fulfilled one of the criteria below was defined as a clinically relevant bleeding event:
|
upto 15 weeks
|
Frequency (Occurrence Rates) of Nuisance Bleeding Event
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with nuisance bleeding event Any bleed that did not qualify as a major bleed was defined as a minor bleed; all minor bleeding events not fulfilling one of the criteria below was defined as a nuisance bleeding event:
|
Upto 15 weeks
|
Incidence and Severity of Adverse Events
Aikaikkuna: Upto 15 weeks
|
Intensity of event is categorised as mild, moderate and severe.
|
Upto 15 weeks
|
Discontinuation of the Study Drug Due to Adverse Events
Aikaikkuna: Upto 15 weeks
|
Discontinuation of the study drug due to adverse events.
|
Upto 15 weeks
|
Changes in Laboratory Test Values
Aikaikkuna: 12 weeks
|
The number of patients with ALT, AST, alkaline phosphatase, or bilirubin exceeded the upper limit of normal (ULN) range
|
12 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Frequency (Occurrence Rates) of a Composite Clinical Endpoint.
Aikaikkuna: Upto 15 weeks
|
Percentage of patients with the composite clinical endpoint (ischemic or haemorrhagic stroke (fatal or non-fatal), transient ischemic attacks, systemic embolism, myocardial infarction (fatal or non-fatal), other major adverse cardiac events, and death)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Ischemic or Haemorrhagic Stroke (Fatal or Non-fatal)
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with ischemic or haemorrhagic stroke (fatal or non-fatal)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Transient Ischemic Attack
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with transient ischemic attack
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Systemic Embolism
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with systemic embolism
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Myocardial Infarction (Fatal or Non-fatal)
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with myocardial infarction (fatal or non-fatal)
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Other Major Adverse Cardiac Events
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with other major adverse cardiac events
|
Upto 15 weeks
|
Frequency (Occurrence Rates) of Death
Aikaikkuna: Upto 15 weeks
|
The percentage of patients with death
|
Upto 15 weeks
|
Anticoagulation Effects Trough aPTT (Activated Partial Thromboplastin Time)
Aikaikkuna: Week 0,1,4 and 12
|
The blood coagulation parameter aPTT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough ECT (Ecarin Clotting Time)
Aikaikkuna: Week 0,1,4 and 12
|
The blood coagulation parameter ECT was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough INR (International Normalised Ratio)
Aikaikkuna: Week 0,1,4 and 12
|
The blood coagulation parameter INR was assessed in patients allocated to the dabigatran etexilate groups at week 0, prior to drug administration and at the trough at week 1, 4 and 12.
|
Week 0,1,4 and 12
|
Anticoagulation Effects Trough 11-dehydrothromboxane B2
Aikaikkuna: Week 0 and 12
|
Analysis based on concomitant use of aspirin compared to no aspirin users.
11-dehydrothromboxane B2 is measured in urine of patients.
|
Week 0 and 12
|
Steady-state Pharmacokinetics of Total Dabigatran Trough Plasma Concentration
Aikaikkuna: Week 1,4 and 12
|
Week 1,4 and 12
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 1160.49
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Eteisvärinä
-
Pusan National University HospitalEi vielä rekrytointiaSydämen istutettava elektroninen laite | Atrial High Rate -jaksoKorean tasavalta
-
Assiut UniversityPeruutettuASD2 (Secundum Atrial Septal Defect)
-
Occlutech International ABValmisSecundum eteisen väliseinävauriot
-
Carag AGValmis
-
W.L.Gore & AssociatesValmisVälikalvon vika, eteisYhdysvallat
-
Institute of Cardiology, Warsaw, PolandTuntematonOstium Secundum eteisen väliseinän vikaPuola